Discovery of Evobrutinib: An Oral, Potent, and Highly Selective, Covalent Bruton’s Tyrosine Kinase (BTK) Inhibitor for the Treatment of Immunological Diseases-Reference-Cited by-同舟云学术

Discovery of Evobrutinib: An Oral, Potent, and Highly Selective, Covalent Bruton’s Tyrosine Kinase (BTK) Inhibitor for the Treatment of Immunological Diseases

Published:2019-08-01 Issue:17 Volume:62 Page:7643-7655
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Caldwell Richard D.¹,Qiu Hui¹,Askew Ben C.¹,Bender Andrew T.¹,Brugger Nadia¹,Camps Montserrat¹,Dhanabal Mohanraj¹,Dutt Vikram¹,Eichhorn Thomas¹,Gardberg Anna S.¹,Goutopoulos Andreas¹,Grenningloh Roland¹,Head Jared¹,Healey Brian¹,Hodous Brian L.¹,Huck Bayard R.¹,Johnson Theresa L.¹,Jones Christopher¹,Jones Reinaldo C.¹,Mochalkin Igor¹,Morandi Federica¹,Nguyen Ngan¹,Meyring Michael¹,Potnick Justin R.¹,Santos Dusica Cvetinovic¹,Schmidt Ralf¹,Sherer Brian¹,Shutes Adam¹,Urbahns Klaus¹,Follis Ariele Viacava¹,Wegener Ansgar A.¹,Zimmerli Simone C.¹,Liu-Bujalski Lesley¹

Affiliation:

1. EMD Serono Research & Development Institute, Inc. (a Business of Merck KGaA, Darmstadt, Germany), 45 A Middlesex Turnpike, Billerica, Massachusetts 01821, United States

Funder

EMD Serono

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.9b00794

Reference27 articles.

1. Btk function in B cell development and response

2. Sustained correction of B-cell development and function in a murine model of X-linked agammaglobulinemia (XLA) using retroviral-mediated gene transfer

3. Regulation of B Lymphocyte Development and Activation by Bruton's Tyrosine Kinase

4. Bruton’s Tyrosine Kinase Is Not Essential for B Cell Survival beyond Early Developmental Stages

Cited by 106 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comprehensive Characterization of BTK Inhibitor Specificity, Potency, and Biological Effects: Insights into Covalent and Non-covalent Mechanistic Signatures;2024-09-08

2. In vivo Bruton’s tyrosine kinase inhibition attenuates alcohol-associated liver disease by regulating CD84-mediated granulopoiesis;Science Translational Medicine;2024-08-07

3. Therapeutic potential and recent progression of BTK inhibitors against rheumatoid arthritis;Chemical Biology & Drug Design;2024-07

4. Discovery and Preclinical Characterization of BIIB129, a Covalent, Selective, and Brain-Penetrant BTK Inhibitor for the Treatment of Multiple Sclerosis;Journal of Medicinal Chemistry;2024-05-07

5. Inhibitors of Bruton's tyrosine kinase as emerging therapeutic strategy in autoimmune diseases;Autoimmunity Reviews;2024-05